Astellas Completes OSI Acquisition; Shares Jump In Tokyo
This article was originally published in PharmAsia News
Executive Summary
Astellas announced the completion of its acquisition of OSI Pharmaceuticals, obtaining 93 percent of OSI Pharmaceuticals' publicly traded shares. The New York-based company immediately became a wholly owned subsidiary of Astellas U.S. Holding